Causes of Alzheimer's disease: Paracetamol (acetaminophen) today? Amphetamines tomorrow?

Medical Hypotheses

Volumn 56, Issue 1, 2001, Pages 121-123

  Jones, G R N ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE DERIVATIVE; FREE RADICAL; GLUTATHIONE; PARACETAMOL; PHENACETIN;

ALZHEIMER DISEASE; BRAIN INJURY; DRUG METABOLISM; HUMAN; LIPID PEROXIDATION; LIVER TOXICITY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE;

EID: 0035161362     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.2000.1235     Document Type: Article

References (22)

1. Epidemiology of clinically diagnosed Alzheimer's disease
2. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset
3. Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans
4. Epidemiology of dementia and Alzheimer's disease
5. Phenacetin through the looking glass
6. Analgesic abuse and dementia
7. Fate of acetophenetidin (phenacetin) in man and methods for the estimation of acetophenetidin and its metabolites in biological material
8. Risk of Alzheimer's disease and duration of NSAID use
9. Enhanced hepatotoxicity of acetaminophen in the alcoholic patient. Two case reports and a review of the literature
10. Oxidative stress in Alzheimer's disease
11. Mechanisms of the formation and disposition of reactive metabolites that can cause acute liver injury
12. Acute paracetamol intoxication of starved mice leads to lipid peroxidation in vivo
13. Ecstasy and serotonin depletion
14. Ecstasy and neurodegeneration
15. Working memory deficits in current and previous users of MDMA ('ecstasy')
16. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA)
17. Cognitive performance in recreational users of MDMA or 'ecstasy': Evidence for memory deficits
18. Positron emission tomographic evidence of toxic effect of MDMA ('Ecstasy') on brain serotonin neurons in human beings
19. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits
20. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its congeners
21. Methamphetamine-induced serotonin neurotoxicity is mediated by superoxide radicals
22. Methamphetamine-induced changes in antioxidant enzymes and lipid peroxidation in copper/zinc-superoxide dismutase transgenic mice